|Bid||15.46 x 89300|
|Ask||15.72 x 86300|
|Day's Range||15.32 - 15.55|
|52 Week Range||11.22 - 19.94|
|Beta (3Y Monthly)||0.44|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The small-cap biotech now has three of the top 10 pharmaceutical companies using its protein engineering platform technology.
The Redwood City, California-based company said it had a loss of 9 cents per share. Losses, adjusted for stock option expense and non-recurring costs, came to 5 cents per share. The producer of custom ...
Codexis Inc (NASDAQ:CDXS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
The small biotech met 2018 guidance and expects another year of growth, but one segment's growth disappoints.
Codexis stock approached a breakout Tuesday after the biotech company struck a deal with Dow Jones giant Merck for its protein-engineering technology. The platform is called CodeEvolver.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) Axsome Therapeutics ...
Codexis is on pace to become the first publicly-traded synthetic biology company to deliver consistent operating profits. Investors should take note.
Codexis (CDXS) delivered earnings and revenue surprises of 100.00% and 15.81%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Redwood City, California-based company said it had a loss of 4 cents. Earnings, adjusted for stock option expense and non-recurring costs, were less than 1 cent on a per-share ...
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Both stocks have gained over 140% in the last year alone. Both are looking forward to growth from innovative sweetener ingredients. One doesn't belong in your portfolio.
The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor
For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...
Codexis (CDXS) delivered earnings and revenue surprises of 83.33% and 14.09%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Redwood City, California-based company said it had a loss of 7 cents per share. Losses, adjusted for stock option expense and non-recurring costs, came to 2 cents per share. The producer of custom ...